Canagliflozin vs Ertugliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson and partners
NCT01032629 · Phase 3 · completed
The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.
Next expected readout: December 2026 · NCT05427084 (registry estimate)
Reported efficacy
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline (Day 1) and Week 26); Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)): Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). (met)
Result source: NCT03170518
Ertugliflozin · Steglatro
Marketed by Merck & Co. and partners
NCT01986881 · Phase 3 · completed
This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.
Next expected readout: January 2028 · NCT07621380 (registry estimate)
Reported efficacy
Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years); Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) (Baseline and Week 18): Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years (met)
Result source: NCT01986881
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Canagliflozin | Ertugliflozin |
|---|---|---|
| HbA1c, change | -0.4% vs 0.4%−0.8 vs placeboNCT0317051841 other results
| -1.0% vs 0.2%−1.2 vs placeboNCT0195867165 other results
|
| Body weight, change (kg) | -2.9 vs -0.8−2.1 vs placeboNCT006422788 other results
| -3.8 vs -1.3−2.5 vs placeboNCT0198688143 other results
|
| HbA1c below 7% | 42.8% vs 43%vs Metformin XRNCT018093276 other results
| 28.2% vs 15.5%+12.7 vs placeboNCT0198688143 other results
|
| Fasting plasma glucose, change | -0.6 vs 0.2−0.7 vs placeboNCT0103262934 other results
| -1.6 vs -0.5−1.1 vs placeboNCT0198688163 other results
|
| 3-point MACE (% with event) | —Not posted · NCT04304261 | —Not posted · NCT03717194 |
HbA1c, change
- Canagliflozin
- -0.4% vs 0.4%−0.8 vs placeboNCT03170518
41 other results
- -0.7% vs -0.0% NCT01106651
- -0.4% vs -0.0% NCT01064414
- -1.0% vs -0.3% NCT01106690
- -1.1% vs -0.1% NCT01106625
- -1.0% vs 0.1% NCT01081834
- -1.1% vs -0.5% NCT01381900
- -0.6% vs -0.0% NCT01106651
- -0.3% vs -0.0% NCT01064414
- -0.9% vs -0.3% NCT01106690
- -0.8% vs -0.1% NCT01106625
- -0.8% vs 0.1% NCT01081834
- -1.0% vs -0.5% NCT01381900
- -1.0% vs -0.1% NCT02354235
- -0.9% vs -0.8% NCT00968812
- -1.0% vs -0.7% NCT01137812
- -1.4% vs -1.3% NCT01809327
- -0.9% vs -0.8% NCT01106677
- -0.8% vs -0.8% NCT00968812
- -1.4% vs -1.3% NCT01809327
- -0.8% vs -0.8% NCT01106677
- -1.8% vs -1.3% NCT01809327
- -1.8% vs -1.3% NCT01809327
- -0.3% vs 0.0% NCT01032629
- -0.3% vs 0.0% NCT01032629
- -0.3% vs 0.7% NCT03170518
- -0.6% vs 0.1% NCT03170518
- -0.7% vs -0.6% NCT00968812
- -0.9% vs -0.7% NCT01106677
- -0.7% vs -0.6% NCT00968812
- -0.7% vs -0.7% NCT01106677
- -0.9% vs -0.2% NCT00642278
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.2% NCT00642278
- -0.7% vs -0.2% NCT00642278
- -0.6% vs -0.0% NCT01340664
- -0.5% vs -0.0% NCT01340664
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.0% NCT02025907
- -1.0% vs 0.1% NCT02220920
- -0.9% vs -1.1% NCT02622113
- 7.8% vs 8.3% NCT02964585
- Ertugliflozin
- -1.0% vs 0.2%−1.2 vs placeboNCT01958671
65 other results
- -0.9% vs -0.0% NCT02033889
- -0.9% vs -0.1% NCT02036515
- -0.4% vs -0.3% NCT01986855
- -0.9% vs -0.2% NCT02630706
- -0.8% vs -0.2% NCT01986881
- -0.8% vs -0.2% NCT01986881
- -0.8% vs -0.6% NCT01986881
- -1.0% vs -0.2% NCT01986881
- -0.8% vs 0.2% NCT01958671
- -0.7% vs -0.0% NCT02033889
- -0.8% vs -0.1% NCT02036515
- -0.3% vs -0.3% NCT01986855
- -1% vs -0.2% NCT02630706
- -0.9% vs -0.6% NCT01986881
- -0.9% vs -0.2% NCT01986881
- -1.7% vs -0.4% NCT02226003
- -1.6% vs -0.4% NCT02226003
- -0.6% vs 0.1% NCT04029480
- -0.6% vs -0.7% NCT01999218
- -1.1% vs -1.1% NCT02099110
- -0.6% vs -0.7% NCT01999218
- -1.0% vs -1.1% NCT02099110
- -1.5% vs -1.1% NCT02099110
- -1.5% vs -1.1% NCT02099110
- -0.5% vs -0.1% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.4% vs -0.0% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.2% vs 0.1% NCT01986881
- -0.5% vs -0.1% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.4% vs -0.0% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.2% vs 0.1% NCT01986881
- -0.3% vs -0.1% NCT01986881
- -0.7% vs -0.7% NCT02033889
- -0.3% vs -0.1% NCT01986881
- -0.9% vs -0.6% NCT02033889
- -1.0% vs -0.7% NCT02033889
- -0.8% vs 0.0% NCT02036515
- -0.4% vs -0.3% NCT01986855
- -0.6% vs -0.6% NCT02033889
- -0.8% vs 0.0% NCT02036515
- -0.3% vs -0.3% NCT01986855
- -0.5% vs 0.3% NCT04029480
- -0.2% vs 0.8% NCT04029480
- -0.4% vs 0.3% NCT04029480
- -0.1% vs 0.2% NCT01986881
- -0.3% vs 0.2% NCT01986881
- -0.8% vs -0.1% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.7% vs -0.1% NCT01059825
- -0.6% vs -0.1% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.5% vs -0.0% NCT01059825
- -0.3% vs 0% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.4% vs -0.0% NCT01059825
- -0.2% vs 0% NCT01059825
- -0.7% vs -0.1% NCT01059825
- -0.5% vs -0.0% NCT01059825
- -0.2% vs 0% NCT01059825
- -0.6% vs -0.1% NCT01059825
- -0.4% vs -0.0% NCT01059825
- -0.1% vs 0% NCT01059825
Body weight, change (kg)
- Canagliflozin
- -2.9 vs -0.8−2.1 vs placeboNCT00642278
8 other results
- -1.5 vs 0.1 NCT01939496
- -2.3 vs -0.8 NCT00642278
- -1.0 vs 0.1 NCT01939496
- -2.9 vs -0.8 NCT00642278
- -2.3 vs -0.8 NCT00642278
- -2.0 vs -0.8 NCT00642278
- -3.5 vs -1.9 NCT02324842
- -6 vs -1.9 NCT02324842
- Ertugliflozin
- -3.8 vs -1.3−2.5 vs placeboNCT01986881
43 other results
- -3.4 vs -1.0 NCT01986881
- -3.2 vs -0.7 NCT01986881
- -2.8 vs -0.4 NCT01986881
- -2.3 vs -0.4 NCT01986881
- -3.4 vs -1.3 NCT01986881
- -3.0 vs -1.0 NCT01986881
- -2.8 vs -0.7 NCT01986881
- -2.5 vs -0.4 NCT01986881
- -2.0 vs -0.4 NCT01986881
- -4.6 vs -1.2 NCT01986881
- -3.6 vs -0.2 NCT02033889
- -3.4 vs 0.1 NCT02033889
- -2.8 vs -0.9 NCT02036515
- -2.9 vs -1.3 NCT02033889
- -2.1 vs -0.3 NCT01986881
- -3.7 vs -1.2 NCT01986881
- -3.6 vs -1.4 NCT01958671
- -3.0 vs -1.3 NCT02036515
- -1.4 vs 0.5 NCT01986855
- -3.2 vs -1.2 NCT02630706
- -3.8 vs -0.2 NCT02033889
- -3.2 vs 0.1 NCT02033889
- -1.9 vs -0.3 NCT01986881
- -1.2 vs -0.7 NCT01986881
- -2.4 vs -0.5 NCT01986881
- -3.5 vs -0.9 NCT02036515
- -3.2 vs -1.4 NCT01958671
- -3.0 vs -1.3 NCT02033889
- -3.4 vs -1.3 NCT02036515
- -1.3 vs 0.5 NCT01986855
- -3.0 vs -1.2 NCT02630706
- -1.8 vs -0.7 NCT01986881
- -2.0 vs -0.5 NCT01986881
- -3.0 vs -0.9 NCT02226003
- -2.9 vs -0.9 NCT02226003
- -7.4 vs -1.0 NCT01986881
- -4.2 vs -1.0 NCT01986881
- -3.4 vs 0.9 NCT01999218
- -3.7 vs -0.7 NCT02099110
- -3.0 vs 0.9 NCT01999218
- -2.7 vs -0.7 NCT02099110
- -2.9 vs -0.7 NCT02099110
- -2.5 vs -0.7 NCT02099110
HbA1c below 7%
- Canagliflozin
- 42.8% vs 43%vs Metformin XRNCT01809327
6 other results
- 38.8% vs 43% NCT01809327
- 56.8% vs 43% NCT01809327
- 49.6% vs 43% NCT01809327
- 57.1% vs 31.5% NCT01340664
- 47.8% vs 31.5% NCT01340664
- 32.3% vs 12.2% NCT02025907
- Ertugliflozin
- 28.2% vs 15.5%+12.7 vs placeboNCT01986881
43 other results
- 29% vs 17.4% NCT01986881
- 23.8% vs 16.6% NCT01986881
- 22.7% vs 16.9% NCT01986881
- 22.7% vs 18.2% NCT01986881
- 28.4% vs 15.5% NCT01986881
- 28.3% vs 17.4% NCT01986881
- 23.9% vs 16.6% NCT01986881
- 23.1% vs 16.9% NCT01986881
- 35.8% vs 13.1% NCT01958671
- 40% vs 15.8% NCT02033889
- 40.8% vs 16.2% NCT02630706
- 21.1% vs 10.7% NCT01986881
- 33.7% vs 19.1% NCT02033889
- 20% vs 16.5% NCT01986881
- 20.7% vs 10.7% NCT01986881
- 24.9% vs 18.2% NCT01986881
- 39.9% vs 17% NCT02036515
- 11.3% vs 12.1% NCT01986855
- 36.6% vs 30.6% NCT02033889
- 35.3% vs 15.8% NCT02033889
- 34.8% vs 30.6% NCT02033889
- 24.6% vs 19.1% NCT02033889
- 18.6% vs 16.5% NCT01986881
- 27.8% vs 25% NCT01986881
- 32.7% vs 12.8% NCT01986881
- 32.7% vs 13.7% NCT02036515
- 28.2% vs 13.1% NCT01958671
- 32.1% vs 17% NCT02036515
- 16.2% vs 12.1% NCT01986855
- 38.2% vs 16.2% NCT02630706
- 32.7% vs 25% NCT01986881
- 37% vs 12.8% NCT01986881
- 33.3% vs 13.7% NCT02036515
- 31.3% vs 8.3% NCT02226003
- 35.7% vs 8.3% NCT02226003
- 31.9% vs 32.8% NCT02099110
- 26.4% vs 32.8% NCT02099110
- 49.2% vs 32.8% NCT02099110
- 52.3% vs 32.8% NCT02099110
- 42.9% vs 15.6% NCT01059825
- 36.2% vs 15.6% NCT01059825
- 38.6% vs 15.6% NCT01059825
- 44% vs 15.6% NCT01059825
Fasting plasma glucose, change
- Canagliflozin
- -0.6 vs 0.2−0.7 vs placeboNCT01032629
34 other results
- -0.4 vs 0.2 NCT01032629
- -1.1 vs 0.4 NCT01106651
- -0.7 vs 0.0 NCT01064414
- -1.8 vs 0.1 NCT01106690
- -1.7 vs 0.2 NCT01106625
- -1.9 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1 vs 0.4 NCT01106651
- -0.8 vs 0.0 NCT01064414
- -1.5 vs 0.1 NCT01106690
- -1.0 vs 0.2 NCT01106625
- -1.5 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1.9 vs 0.2 NCT02354235
- -1.9 vs -1.0 NCT01106677
- -1.7 vs -0.3 NCT01137812
- -2.1 vs -1.1 NCT01106677
- -1.4 vs -1.0 NCT01106677
- -1.5 vs -1.1 NCT01106677
- 9.7 vs 9.8 NCT02324842
- 10.0 vs 9.8 NCT02324842
- -1.4 vs 0.2 NCT00642278
- -1.3 vs -0.4 NCT01939496
- -1.4 vs 0.2 NCT00642278
- -0.0 vs -0.4 NCT01939496
- -1.3 vs 0.2 NCT00642278
- -1.5 vs 0.2 NCT00642278
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.2 NCT00642278
- -1.6 vs -0.1 NCT02025907
- -1.9 vs -0.1 NCT02220920
- -1.8 vs -1.8 NCT02622113
- 7.9 vs 8.8 NCT02964585
- Ertugliflozin
- -1.6 vs -0.5−1.1 vs placeboNCT01986881
63 other results
- -1.9 vs -0.9 NCT01986881
- -1.4 vs -0.2 NCT01986881
- -1.3 vs -0.2 NCT01986881
- -0.9 vs 0.2 NCT01986881
- -1.6 vs -0.5 NCT01986881
- -1.8 vs -0.9 NCT01986881
- -1.2 vs -0.2 NCT01986881
- -1.1 vs -0.2 NCT01986881
- -1.9 vs -0.7 NCT02033889
- -1.5 vs 0.2 NCT02036515
- -2.2 vs -0.1 NCT02033889
- -1.8 vs -0.4 NCT01986881
- -0.6 vs -0.3 NCT01986881
- -1.6 vs -0.6 NCT02033889
- -1.2 vs -0.7 NCT02033889
- -1.5 vs -0.1 NCT02033889
- -1.5 vs -0.4 NCT01986881
- -0.8 vs 0.2 NCT01986881
- -0.8 vs -0.3 NCT01986881
- -2.4 vs 0.0 NCT01958671
- -1.8 vs -0.1 NCT02036515
- -1.1 vs -0.3 NCT01986855
- -1.9 vs -0.4 NCT02630706
- -1.5 vs -0.8 NCT01986881
- -2.0 vs -0.3 NCT01986881
- -1.4 vs 0.2 NCT02036515
- -1.9 vs 0.0 NCT01958671
- -1.5 vs -0.1 NCT02036515
- -0.7 vs -0.3 NCT01986855
- -2.1 vs -0.4 NCT02630706
- -1.6 vs -0.8 NCT01986881
- -2.0 vs -0.3 NCT01986881
- -1.0 vs -0.6 NCT02033889
- -0.7 vs 1.2 NCT04029480
- -1.1 vs 0.5 NCT04029480
- -4.7 vs 0.8 NCT01986881
- -0.1 vs 0.8 NCT01986881
- -2.0 vs -1.4 NCT02099110
- -2.0 vs -1.4 NCT02099110
- -2.7 vs -1.4 NCT02099110
- -2.4 vs -1.4 NCT02099110
- -1.3 vs 0.1 NCT01059825
- -1.4 vs 0.2 NCT01059825
- -1.7 vs 0.2 NCT01096667
- -1.3 vs 0.3 NCT01059825
- -1.3 vs -0.3 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -1.6 vs 0.1 NCT01059825
- -1.7 vs 0.2 NCT01059825
- -1.7 vs 0.2 NCT01096667
- -1.5 vs 0.3 NCT01059825
- -1.8 vs -0.3 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -1.8 vs 0.1 NCT01059825
- -1.8 vs 0.2 NCT01059825
- -1.6 vs 0.3 NCT01059825
- -1.5 vs 0.3 NCT01059825
- -1.0 vs 0.1 NCT01059825
- -1.0 vs 0.2 NCT01059825
- -0.8 vs 0.2 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -0.6 vs -0.3 NCT01096667
- -0.8 vs 0.3 NCT01059825
3-point MACE (% with event)
- Canagliflozin
- —Not posted · NCT04304261
- Ertugliflozin
- —Not posted · NCT03717194
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
13 other shared endpoints and safety
Coverage. Canagliflozin: 17 of 17 rows · Ertugliflozin: 17 of 17 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Canagliflozin Rows use multiple source trials | Ertugliflozin Rows use multiple source trials |
|---|---|---|
| Ambulatory Day DBP absolute change · mmHg | -3.23 vs -0.2 placebo mmHg @ 6wk300 mga,b,c,d,e NCT01939496 · Phase 4 · registry result, not featured evidence show 1 more dose-2.39 vs -0.2 placebo mmHg @ 6wk100 mg NCT01939496 · Phase 4 · registry result, not featured evidence | -1.88 vs 0.87 placebo mmHg @ 4wk5 mga,b,c,d,e NCT01096667 · Phase 2 · registry result, not featured evidence show 2 more doses-1.77 vs 0.87 placebo mmHg @ 4wk25 mg NCT01096667 · Phase 2 · registry result, not featured evidence -2.12 vs 0.87 placebo mmHg @ 4wk1 mg NCT01096667 · Phase 2 · registry result, not featured evidence |
| Ambulatory Day SBP absolute change · mmHg | -7.36 vs -0.65 placebo mmHg @ 6wk300 mga,b,c,d,e NCT01939496 · Phase 4 · registry result, not featured evidence show 1 more dose-5.05 vs -0.65 placebo mmHg @ 6wk100 mg NCT01939496 · Phase 4 · registry result, not featured evidence | -3.61 vs 0.82 placebo mmHg @ 4wk5 mga,b,c,d,e NCT01096667 · Phase 2 · registry result, not featured evidence show 2 more doses-4.17 vs 0.82 placebo mmHg @ 4wk25 mg NCT01096667 · Phase 2 · registry result, not featured evidence -2.88 vs 0.82 placebo mmHg @ 4wk1 mg NCT01096667 · Phase 2 · registry result, not featured evidence |
| Ambulatory DBP absolute change · mmHg | -3.27 vs -0.26 placebo mmHg @ 6wk300 mga,b,c,d,e NCT01939496 · Phase 4 · registry result, not featured evidence show 1 more dose-2.18 vs -0.26 placebo mmHg @ 6wk100 mg NCT01939496 · Phase 4 · registry result, not featured evidence | -2.34 vs 0.77 placebo mmHg @ 4wk5 mga,b,c,d,e NCT01096667 · Phase 2 · registry result, not featured evidence show 2 more doses-1.5 vs 0.77 placebo mmHg @ 4wk25 mg NCT01096667 · Phase 2 · registry result, not featured evidence -1.89 vs 0.77 placebo mmHg @ 4wk1 mg NCT01096667 · Phase 2 · registry result, not featured evidence |
| Ambulatory Night DBP absolute change · mmHg | -3.42 vs -0.98 placebo mmHg @ 6wk300 mga,b,c,d,e NCT01939496 · Phase 4 · registry result, not featured evidence show 1 more dose-1.73 vs -0.98 placebo mmHg @ 6wk100 mg NCT01939496 · Phase 4 · registry result, not featured evidence | -2.52 vs 1.02 placebo mmHg @ 4wk5 mga,b,c,d,e NCT01096667 · Phase 2 · registry result, not featured evidence show 2 more doses-0.84 vs 1.02 placebo mmHg @ 4wk25 mg NCT01096667 · Phase 2 · registry result, not featured evidence -1.48 vs 1.02 placebo mmHg @ 4wk1 mg NCT01096667 · Phase 2 · registry result, not featured evidence |
| Ambulatory Night SBP absolute change · mmHg | -6.98 vs -3.49 placebo mmHg @ 6wk300 mga,b,c,d,e NCT01939496 · Phase 4 · registry result, not featured evidence show 1 more dose-4.33 vs -3.49 placebo mmHg @ 6wk100 mg NCT01939496 · Phase 4 · registry result, not featured evidence | -3.47 vs -0.29 placebo mmHg @ 4wk5 mga,b,c,d,e NCT01096667 · Phase 2 · registry result, not featured evidence show 2 more doses-2.31 vs -0.29 placebo mmHg @ 4wk25 mg NCT01096667 · Phase 2 · registry result, not featured evidence -2.48 vs -0.29 placebo mmHg @ 4wk1 mg NCT01096667 · Phase 2 · registry result, not featured evidence |
| Ambulatory SBP absolute change · mmHg | -7.31 vs -1.26 placebo mmHg @ 6wk300 mga,b,c,d,e NCT01939496 · Phase 4 · registry result, not featured evidence show 1 more dose-4.78 vs -1.26 placebo mmHg @ 6wk100 mg NCT01939496 · Phase 4 · registry result, not featured evidence | -3.73 vs 0.26 placebo mmHg @ 4wk5 mga,b,c,d,e NCT01096667 · Phase 2 · registry result, not featured evidence show 2 more doses-3.42 vs 0.26 placebo mmHg @ 4wk25 mg NCT01096667 · Phase 2 · registry result, not featured evidence -2.71 vs 0.26 placebo mmHg @ 4wk1 mg NCT01096667 · Phase 2 · registry result, not featured evidence |
| eGFR absolute change · mL | -3.98 vs -5.23 placebo mL @ 338wk300 mga,f,g,h NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more dose-3.55 vs -5.23 placebo mL @ 338wk100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 0.2 vs -1.8 placebo mL @ 312wk15 mga,f,g,h NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 1 more dose3.7 vs -1.8 placebo mL @ 312wk5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 |
| Fasting Plasma Glucose Change mg/dL absolute change · mg | -11.5 vs 15.3 placebo mg @ 26wk100/300 mgi,d NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 | -55.36 vs -9.3 placebo mg @ 26wk15 mg + 100 mga,i,d NCT02226003 · Phase 3 · combination show 1 more dose-48.25 vs -9.3 placebo mg @ 26wk5 mg + 100 mg NCT02226003 · Phase 3 · combination |
| Glycemic Rescue responder rate · % of participants | 11.9% (n=84) vs 46% (n=87) placebo100/300 mgi,d,j NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 | 10.7% (n=205) vs 24.4% (n=209) placebo @ 104wk15 mga,i,d,j NCT02033889 · Phase 3 show 1 more dose11.1% (n=207) vs 24.4% (n=209) placebo @ 104wk5 mg NCT02033889 · Phase 3 |
| SBP absolute change · mmHg | -5.76 vs 0.09 placebo mmHg @ 26wkk,c,d NCT02025907 · Phase 4 · registry result, not featured evidence 14 other source trials-2.24 vs -0.33 Metformin XR mmHg @ 26wk NCT01809327 · Phase 3 · registry result, not featured evidence · combination -2.24 vs -0.33 Metformin XR mmHg @ 26wk100 mg NCT01809327 · Phase 3 · registry result, not featured evidence -2.36 vs -0.33 Metformin XR mmHg @ 26wk300 mg NCT01809327 · Phase 3 · registry result, not featured evidence -1.65 vs -0.33 Metformin XR mmHg @ 26wk NCT01809327 · Phase 3 · registry result, not featured evidence · combination -3.52 vs 1.1 placebo mmHg @ 26wk100 mg NCT01106651 · Phase 3 · registry result, not featured evidence -6.79 vs 1.1 placebo mmHg @ 26wk300 mg NCT01106651 · Phase 3 · registry result, not featured evidence -5.3 vs -1.24 placebo mmHg @ 26wk100 mg NCT01106690 · Phase 3 · registry result, not featured evidence -4.7 vs -1.24 placebo mmHg @ 26wk300 mg NCT01106690 · Phase 3 · registry result, not featured evidence -3.84 vs -1.83 Sitagliptin mmHg @ 26wk100 mg NCT01106677 · Phase 3 · registry result, not featured evidence -5.06 vs -1.83 Sitagliptin mmHg @ 26wk300 mg NCT01106677 · Phase 3 · registry result, not featured evidence -4.89 vs -2.65 placebo mmHg @ 26wk100 mg NCT01106625 · Phase 3 · registry result, not featured evidence -4.27 vs -2.65 placebo mmHg @ 26wk300 mg NCT01106625 · Phase 3 · registry result, not featured evidence -3.34 vs 0.38 placebo mmHg @ 26wk100 mg NCT01081834 · Phase 3 · registry result, not featured evidence -5.04 vs 0.38 placebo mmHg @ 26wk300 mg NCT01081834 · Phase 3 · registry result, not featured evidence | -3.98 vs 2.41 placebo mmHg @ 26wk15 mg + 100 mga,k,c,d NCT02226003 · Phase 3 · combination show 1 more dose-2.04 vs 2.41 placebo mmHg @ 26wk5 mg + 100 mg NCT02226003 · Phase 3 · combination |
| Seated DBP absolute change · mmHg | -0.2 vs 0.7 placebo mmHg @ 52wk100/300 mgl,d NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 | -0.95 vs -0.15 placebo mmHg @ 52wk15 mga,l,d NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 1 more dose-0.97 vs -0.15 placebo mmHg @ 52wk5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 |
| Seated SBP absolute change · mmHg | 0 vs 1.5 placebo mmHg @ 52wk100/300 mgl,d NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 | -2.41 vs 0.75 placebo mmHg @ 52wk15 mga,l,d NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 1 more dose-1.84 vs 0.75 placebo mmHg @ 52wk5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 |
| Weight percent change · % of baseline | -2.14% (n=75) vs -1.4% (n=65) placebob,c,d,j NCT02622113 · Phase 4 · registry result, not featured evidence · combination 5 other source trials-2.6% (n=64) vs -1.1% (n=62) placebo @ 12wk100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence -2.7% (n=63) vs -1.1% (n=62) placebo @ 12wk200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence -3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence -3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence -2.3% (n=63) vs -1.1% (n=62) placebo @ 12wk50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence | -2.5% (n=53) vs -0.75% (n=51) placebo @ 12wk5 mga,b,c,d,j NCT01059825 · Phase 2 · registry result, not featured evidence show 3 more doses-2.66% (n=50) vs -0.75% (n=51) placebo @ 12wk25 mg NCT01059825 · Phase 2 · registry result, not featured evidence -2.9% (n=51) vs -0.75% (n=51) placebo @ 12wk10 mg NCT01059825 · Phase 2 · registry result, not featured evidence -1.9% (n=54) vs -0.75% (n=51) placebo @ 12wk1 mg NCT01059825 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 6.1%300 mgm NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results7%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 33.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 29%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 0.7%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence 1.2% NCT01989754 · Phase 4 · registry result, not featured evidence 13.2% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 11.1% NCT02025907 · Phase 4 · registry result, not featured evidence 3.9% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 3.6%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 5.3%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 9.2%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 11%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 10.5%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 5.1%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 24.6%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 23.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 5.3%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 4%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 7.9%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 16.7%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.4%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 8%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 12%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 12.5%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 17.3%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 17.8%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 32.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 14%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 8.6%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 12.5%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 10.9%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 13.8%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 13.3%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | —15 mgn NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results—15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.6%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15.8%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.2%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.2%15 mg NCT02033889 · Phase 3 9.7%5 mg NCT02033889 · Phase 3 22.9%15 mg NCT01999218 · Phase 3 24.3%5 mg NCT01999218 · Phase 3 12.5%15 mg NCT02099110 · Phase 3 9.6%5 mg NCT02099110 · Phase 3 11%15 mg + 100 mg NCT02099110 · Phase 3 · combination 9.1%5 mg + 100 mg NCT02099110 · Phase 3 · combination 7.7%15 mg NCT02036515 · Phase 3 —15 mg NCT02036515 · Phase 3 · combination 3.2%5 mg NCT02036515 · Phase 3 —5 mg NCT02036515 · Phase 3 · combination 1%15 mg + 100 mg NCT02226003 · Phase 3 · combination 2%5 mg + 100 mg NCT02226003 · Phase 3 · combination 9%15 mg NCT01986855 · Phase 3 8.2%5 mg NCT01986855 · Phase 3 —15 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 5.3%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 4.1%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence 0% NCT03416270 · Phase 2 · registry result, not featured evidence 5.3%5 mg NCT01096667 · Phase 2 · registry result, not featured evidence 7.7%25 mg NCT01096667 · Phase 2 · registry result, not featured evidence 5.1%1 mg NCT01096667 · Phase 2 · registry result, not featured evidence —5 mg NCT01059825 · Phase 2 · registry result, not featured evidence —25 mg NCT01059825 · Phase 2 · registry result, not featured evidence —10 mg NCT01059825 · Phase 2 · registry result, not featured evidence —1 mg NCT01059825 · Phase 2 · registry result, not featured evidence 39.3% NCT04167761 · Phase 1 · registry result, not featured evidence —15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence —1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —300 mgm NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results—100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.5%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT02065791 · Phase 3 — NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence — NCT01989754 · Phase 4 · registry result, not featured evidence 5.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 0.9% NCT02025907 · Phase 4 · registry result, not featured evidence 1.3% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 4.6% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.3%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 3.4%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 1.7%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 9.7%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.1%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 4.4%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 0.9%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 1.6%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.9%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 7.5%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.1%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 3.1%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 4.7%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 3.1%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence —Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence —Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | —15 mgn NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results—15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.7%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5%15 mg NCT02033889 · Phase 3 0.5%5 mg NCT02033889 · Phase 3 1.6%15 mg NCT01999218 · Phase 3 2%5 mg NCT01999218 · Phase 3 2%15 mg NCT02099110 · Phase 3 1.2%5 mg NCT02099110 · Phase 3 0.8%15 mg + 100 mg NCT02099110 · Phase 3 · combination 1.2%5 mg + 100 mg NCT02099110 · Phase 3 · combination 0.6%15 mg NCT02036515 · Phase 3 —15 mg NCT02036515 · Phase 3 · combination 0.6%5 mg NCT02036515 · Phase 3 —5 mg NCT02036515 · Phase 3 · combination —15 mg + 100 mg NCT02226003 · Phase 3 · combination —5 mg + 100 mg NCT02226003 · Phase 3 · combination 0%15 mg NCT01986855 · Phase 3 0.6%5 mg NCT01986855 · Phase 3 —15 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 0.6%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 1.2%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence — NCT03416270 · Phase 2 · registry result, not featured evidence —5 mg NCT01096667 · Phase 2 · registry result, not featured evidence —25 mg NCT01096667 · Phase 2 · registry result, not featured evidence —1 mg NCT01096667 · Phase 2 · registry result, not featured evidence —5 mg NCT01059825 · Phase 2 · registry result, not featured evidence —25 mg NCT01059825 · Phase 2 · registry result, not featured evidence —10 mg NCT01059825 · Phase 2 · registry result, not featured evidence —1 mg NCT01059825 · Phase 2 · registry result, not featured evidence — NCT04167761 · Phase 1 · registry result, not featured evidence —15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence —1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 42.1%300 mgm NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results41.6%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.7%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.7%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.9%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 33.5%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 17.6% NCT02920918 · Phase 4 · registry result, not featured evidence 24.6% NCT01989754 · Phase 4 · registry result, not featured evidence 9.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 7% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 1.9% NCT02025907 · Phase 4 · registry result, not featured evidence 4% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 1.4% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 3%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 18.2%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.4%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 16.6%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 1.8%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 23.6%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.1%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 20%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 6.1%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 7.1%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 2.7%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.8%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.2%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 4.5%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 2.3%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 1%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 2.5%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 0%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 6.4%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 3.2%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 0%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.6%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 0%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | 7.3%15 mgn NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results7.1%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 34.1%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.9%15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.5%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 7%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 34.9%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.3%5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.9%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.1%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.8%15 mg NCT02033889 · Phase 3 9.7%5 mg NCT02033889 · Phase 3 7.4%15 mg NCT01999218 · Phase 3 9.2%5 mg NCT01999218 · Phase 3 2%15 mg NCT02099110 · Phase 3 4.8%5 mg NCT02099110 · Phase 3 4.9%15 mg + 100 mg NCT02099110 · Phase 3 · combination 3.7%5 mg + 100 mg NCT02099110 · Phase 3 · combination —15 mg NCT02036515 · Phase 3 2%15 mg NCT02036515 · Phase 3 · combination —5 mg NCT02036515 · Phase 3 8.3%5 mg NCT02036515 · Phase 3 · combination 3.1%15 mg + 100 mg NCT02226003 · Phase 3 · combination 2%5 mg + 100 mg NCT02226003 · Phase 3 · combination 19.4%15 mg NCT01986855 · Phase 3 16.5%5 mg NCT01986855 · Phase 3 3.8%15 mg NCT04029480 · Phase 3 · registry result, not featured evidence 3.2%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 0%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 4.5%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 5.9%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 5.3%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence 17.6% NCT03416270 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01096667 · Phase 2 · registry result, not featured evidence 0%25 mg NCT01096667 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01096667 · Phase 2 · registry result, not featured evidence 3.6%5 mg NCT01059825 · Phase 2 · registry result, not featured evidence 1.8%25 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0%10 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0% NCT04167761 · Phase 1 · registry result, not featured evidence 0%15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 300 mgm hypoglycaemia 14.6% (placebo 12.1%) nasopharyngitis 14.1% (placebo 15.3%) urinary tract infection 11% (placebo 8.9%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 59 more results100 mg nasopharyngitis 15.6% (placebo 15.3%) hypoglycaemia 12.5% (placebo 12.1%) upper respiratory tract infection 10.9% (placebo 11.3%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 11.3% diarrhoea 8% upper respiratory tract infection 7.8% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 7.6% diarrhoea 6.8% upper respiratory tract infection 5.6% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 9.7% urinary tract infection 9.1% upper respiratory tract infection 7.5% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 6.8% back pain 6% urinary tract infection 5.4% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg urinary tract infection 29.4% (placebo 4.6%) urinary tract infection 29.4% (placebo 4.6%) nausea 11.8% (placebo 1.1%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg headache 11.9% (placebo 3.4%) headache 11.9% (placebo 3.4%) nasopharyngitis 11.9% (placebo 5.7%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg hypoglycaemia 9.7% (placebo 10.3%) urinary tract infection 9.2% (placebo 8.4%) hypertension 6.5% (placebo 8.8%) NCT02065791 · Phase 3 300 mg fatigue 3.2% diarrhoea 1.6% discomfort 1.6% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 17.6% hypotensive event 11.8% arrhythmic events 5.9% NCT02920918 · Phase 4 · registry result, not featured evidence balanoposthitis 3.2% (placebo 0.9%) NCT01989754 · Phase 4 · registry result, not featured evidence blood glucose decreased 40% (placebo 23.9%) hypoglycaemia 38.7% (placebo 32.8%) nasopharyngitis 34.7% (placebo 25.4%) NCT02622113 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 33.8% gastroenteritis 9.9% hypoglycaemia 9.9% NCT02227849 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 5.6% (placebo 5.6%) back pain 2.8% (placebo 0.9%) depression 2.8% (placebo 0%) NCT02025907 · Phase 4 · registry result, not featured evidence blood glucose decreased 26.7% (placebo 16.9%) hypoglycaemia 25.3% (placebo 21.1%) nasopharyngitis 16% (placebo 18.3%) NCT02220920 · Phase 4 · registry result, not featured evidence · combination 300 mg pollakiuria 5.4% (placebo 1.8%) nasopharyngitis 0% (placebo 0%) NCT01939496 · Phase 4 · registry result, not featured evidence 100 mg nasopharyngitis 5.3% (placebo 0%) pollakiuria 1.8% (placebo 1.8%) NCT01939496 · Phase 4 · registry result, not featured evidence nasopharyngitis 30.7% pollakiuria 6.5% constipation 5.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 18.6% (placebo 16.2%) NCT02354235 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 3.8% upper respiratory tract infection 2.5% back pain 2.1% NCT01809327 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 3.8% glomerular filtration rate decreased 2.5% influenza 2.5% NCT01809327 · Phase 3 · registry result, not featured evidence diarrhoea 4.2% headache 3% influenza 3% NCT01809327 · Phase 3 · registry result, not featured evidence · combination diarrhoea 4.2% headache 3.8% influenza 3.4% NCT01809327 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 18.6% (placebo 15.2%) hypoglycaemia 15.3% (placebo 19.8%) urinary tract infection 14.8% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 9.7% (placebo 19.8%) nasopharyngitis 8.1% (placebo 15.2%) urinary tract infection 7.2% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 18.7% (placebo 15.2%) hypoglycaemia 15.4% (placebo 19.8%) urinary tract infection 13.3% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 10.4% (placebo 19.8%) nasopharyngitis 9.5% (placebo 15.2%) influenza 5.8% (placebo 7.6%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 7.5% (placebo 4%) upper respiratory tract infection 5.7% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 9% (placebo 4%) upper respiratory tract infection 3.1% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 11.2% (placebo 4.4%) nasopharyngitis 7.9% (placebo 11.1%) urinary tract infection 7.9% (placebo 5.6%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 22.5% (placebo 4.4%) urinary tract infection 13.5% (placebo 5.6%) nasopharyngitis 10.1% (placebo 11.1%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 14.4% (placebo 4.4%) arthralgia 4.4% (placebo 2.2%) bronchitis 4.4% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 20% (placebo 4.4%) arthralgia 5.6% (placebo 2.2%) bronchitis 5.6% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 9.6% (placebo 5.2%) pollakiuria 6.1% (placebo 0.9%) arthralgia 5.3% (placebo 1.7%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 13.2% (placebo 5.2%) arthralgia 7.9% (placebo 1.7%) urinary tract infection 7.9% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 8% (placebo 6.1%) back pain 7.1% (placebo 2.6%) nasopharyngitis 5.3% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 12.4% (placebo 6.1%) nasopharyngitis 9.7% (placebo 5.2%) back pain 8.8% (placebo 2.6%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 4.9% upper respiratory tract infection 4.9% urinary tract infection 3.5% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.3% upper respiratory tract infection 6.3% urinary tract infection 4.6% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg pollakiuria 5.7% urinary tract infection 4.9% nasopharyngitis 4.1% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 7.3% pollakiuria 5.7% headache 5.2% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.4% (placebo 3.2%) hypoglycaemia 5.8% (placebo 3.8%) nasopharyngitis 5.1% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 7.1% (placebo 3.2%) hypoglycaemia 7.1% (placebo 3.8%) nasopharyngitis 5.8% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 10.8% (placebo 6.4%) hypoglycaemia 7% (placebo 3.8%) urinary tract infection 5.7% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 13.4% (placebo 6.4%) hypoglycaemia 8.3% (placebo 3.8%) urinary tract infection 7.6% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 6.8% (placebo 5.2%) pain in extremity 6.8% (placebo 0%) urinary tract infection 4.5% (placebo 4.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 8.1% (placebo 5.2%) back pain 6.1% (placebo 3.1%) headache 6.1% (placebo 3.6%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 10.2% (placebo 5.2%) headache 8.6% (placebo 3.6%) back pain 7.6% (placebo 3.1%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 6.4% (placebo 4.2%) nasopharyngitis 4.3% (placebo 5.2%) pain in extremity 2.1% (placebo 0%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 7.2% (placebo 3.6%) urinary tract infection 7.2% (placebo 4.2%) nasopharyngitis 5.1% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 9.7% (placebo 3.6%) urinary tract infection 8.2% (placebo 4.2%) nasopharyngitis 7.2% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 17.5% nasopharyngitis 8.8% upper respiratory tract infection 8.8% NCT01137812 · Phase 3 · registry result, not featured evidence 300 mg daily headache 4.7% (placebo 3.1%) nausea 4.7% (placebo 0%) abdominal pain upper 3.1% (placebo 1.5%) NCT00642278 · Phase 2 · registry result, not featured evidence 100 mg daily headache 7.8% (placebo 3.1%) urinary tract infection 3.1% (placebo 6.2%) vulvovaginal mycotic infection 3.1% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence 300 mg twice daily nausea 7.8% (placebo 0%) abdominal pain upper 6.3% (placebo 1.5%) urinary tract infection 4.7% (placebo 6.2%) NCT00642278 · Phase 2 · registry result, not featured evidence 200 mg daily urinary tract infection 9.2% (placebo 6.2%) vulvovaginal mycotic infection 6.2% (placebo 0%) headache 3.1% (placebo 3.1%) NCT00642278 · Phase 2 · registry result, not featured evidence 50 mg daily nasopharyngitis 7.8% (placebo 3.1%) vulvovaginal mycotic infection 6.3% (placebo 0%) nausea 4.7% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence urinary frequency increased 86.7% dry mouth 26.7% light-headedness/dizziness 26.7% NCT02324842 · Phase na · registry result, not featured evidence nausea 53.3% dry mouth 40% constipation 33.3% NCT02324842 · Phase na · registry result, not featured evidence · combination | 15 mgn hypoglycaemia 30.3% (placebo 31.4%) nasopharyngitis 3.5% (placebo 3.2%) upper respiratory tract infection 2.7% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 44 more results15 mg hypoglycaemia 16.8% (placebo 31.4%) nasopharyngitis 4.4% (placebo 3.2%) dizziness 3.5% (placebo 1.2%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg hypoglycaemia 31.1% (placebo 31.4%) urinary tract infection 9.5% (placebo 2%) nasopharyngitis 7.4% (placebo 3.2%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg hypoglycaemia 5.6% (placebo 31.4%) urinary tract infection 1.9% (placebo 2%) back pain 0% (placebo 0.6%) NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 29% (placebo 31.4%) dizziness 2.3% (placebo 1.2%) upper respiratory tract infection 2.3% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 13% (placebo 31.4%) hypertension 4% (placebo 0.6%) hyperglycaemia 3% (placebo 1.7%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 32.2% (placebo 31.4%) urinary tract infection 9.3% (placebo 2%) upper respiratory tract infection 7.2% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 5.5% (placebo 31.4%) back pain 3.6% (placebo 0.6%) hypertension 3.6% (placebo 0.6%) NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15 mg nasopharyngitis 7.2% (placebo 3.9%) upper respiratory tract infection 6.6% (placebo 5.9%) urinary tract infection 6.6% (placebo 12.4%) NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg urinary tract infection 8.3% (placebo 12.4%) vulvovaginal mycotic infection 7.7% (placebo 1.3%) constipation 7.1% (placebo 2.6%) NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg upper respiratory tract infection 10.2% (placebo 15.8%) back pain 9.8% (placebo 4.8%) hypoglycaemia 8.8% (placebo 20.6%) NCT02033889 · Phase 3 5 mg upper respiratory tract infection 11.1% (placebo 15.8%) headache 6.8% (placebo 4.8%) hypoglycaemia 6.8% (placebo 20.6%) NCT02033889 · Phase 3 5 mg upper respiratory tract infection 6.1% urinary tract infection 6.1% headache 5.6% NCT01999218 · Phase 3 15 mg + 100 mg hypoglycaemia 8.2% nasopharyngitis 4.9% urinary tract infection 3.3% NCT02099110 · Phase 3 · combination 5 mg + 100 mg urinary tract infection 5.8% nasopharyngitis 4.9% hypoglycaemia 3.7% NCT02099110 · Phase 3 · combination 15 mg nasopharyngitis 3.9% (placebo 3.3%) hypoglycaemia 3.3% (placebo 7.2%) urinary tract infection 3.3% (placebo 5.2%) NCT02036515 · Phase 3 · combination 5 mg back pain 5.1% (placebo 3.9%) nasopharyngitis 5.1% (placebo 3.3%) hypoglycaemia 4.5% (placebo 7.2%) NCT02036515 · Phase 3 · combination 15 mg + 100 mg urinary tract infection 2.1% (placebo 1%) hyperglycaemia 1% (placebo 6.2%) blood glucose increased 0% (placebo 7.2%) NCT02226003 · Phase 3 · combination 5 mg + 100 mg urinary tract infection 5.1% (placebo 1%) blood glucose increased 3.1% (placebo 7.2%) hyperglycaemia 0% (placebo 6.2%) NCT02226003 · Phase 3 · combination 15 mg hypoglycaemia 20.6% (placebo 29.2%) urinary tract infection 7.7% (placebo 9.7%) upper respiratory tract infection 7.1% (placebo 4.5%) NCT01986855 · Phase 3 5 mg hypoglycaemia 31% (placebo 29.2%) diarrhoea 6.3% (placebo 5.8%) cough 5.7% (placebo 1.3%) NCT01986855 · Phase 3 15 mg hypoglycaemia 19.2% (placebo 12.7%) nausea 15.4% (placebo 7.3%) vomiting 15.4% (placebo 5.5%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 14.3% (placebo 10.9%) hypoglycaemia 11.1% (placebo 12.7%) covid-19 7.9% (placebo 7.3%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg hypoglycaemia 11.5% (placebo 12.7%) nausea 7.7% (placebo 7.3%) vomiting 7.7% (placebo 5.5%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg nausea 13.6% (placebo 7.3%) abdominal pain 9.1% (placebo 5.5%) diarrhoea 9.1% (placebo 7.3%) NCT04029480 · Phase 3 · registry result, not featured evidence 15 mg hyperuricaemia 5.3% (placebo 12%) hypoglycaemia 5.3% (placebo 1.2%) nasopharyngitis 5.3% (placebo 6.6%) NCT02630706 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 5.3% (placebo 6.6%) hypoglycaemia 3.5% (placebo 1.2%) hyperuricaemia 2.9% (placebo 12%) NCT02630706 · Phase 3 · registry result, not featured evidence 5 mg genital infection fungal 7.9% (placebo 0%) athralgia 5.3% (placebo 0%) nasopharyngitis 5.3% (placebo 0%) NCT01096667 · Phase 2 · registry result, not featured evidence 25 mg fatigue 5.1% (placebo 0%) polyuria 5.1% (placebo 0%) dizziness 2.6% (placebo 5.3%) NCT01096667 · Phase 2 · registry result, not featured evidence 1 mg musculoskeletal pain 5.1% (placebo 0%) upper respiratory tract infection 2.6% (placebo 5.3%) urinary tract infection 2.6% (placebo 2.6%) NCT01096667 · Phase 2 · registry result, not featured evidence 5 mg arthralgia 10.9% (placebo 1.9%) headache 7.3% (placebo 3.7%) hypoglycaemia 5.5% (placebo 0%) NCT01059825 · Phase 2 · registry result, not featured evidence 25 mg genital infection fungal 7.3% (placebo 1.9%) diarrhoea 5.5% (placebo 1.9%) upper respiratory tract infection 5.5% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 10 mg urinary tract infection 9.1% (placebo 7.4%) genital infection fungal 5.5% (placebo 1.9%) upper respiratory tract infection 5.5% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 1 mg arthralgia 3.7% (placebo 1.9%) diarrhoea 3.7% (placebo 1.9%) upper respiratory tract infection 3.7% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 15 mg Oral + 100 ug Oral nasal congestion 12.5% back pain 0% headache 0% NCT02411929 · Phase 1 · registry result, not featured evidence · combination 15 mg Oral + 100 ug IV headache 25% back pain 12.5% nasal congestion 0% NCT02411929 · Phase 1 · registry result, not featured evidence · combination 15 mg decreased appetite 12.5% headache 12.5% tachycardia 12.5% NCT02115347 · Phase 1 · registry result, not featured evidence 15 mg arthralgia 12.5% back pain 12.5% dizziness 12.5% NCT02115347 · Phase 1 · registry result, not featured evidence 4 mg Once Daily diarrhoea 11.5% headache 7.7% abdominal pain 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 2 mg Once Daily headache 11.5% constipation 3.8% dizziness 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 2 mg Twice Daily abdominal pain 3.8% diarrhoea 3.8% dry mouth 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 1 mg Twice Daily headache 12% back pain 4% dyspepsia 4% NCT01054300 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 6 weeks versus 4 weeks.
- fPopulation context differs: baseline_threshold differs (hba1c>=7 versus bmi>=18, hba1c<=10.5, hba1c>=7); comorbidity_diabetes differs (none recorded versus required); prior_therapy differs (unrestricted versus none recorded).
- gTreatment context differs: monotherapy versus combination.
- hAssessment timepoints differ: 338 weeks versus 312 weeks.
- iPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
- jThe assessment timepoint is not available for both results.
- kTrial phases differ: Phase 4 versus Phase 3.
- lPopulation context differs: age eligibility differs (includes children versus adolescents and adults); baseline_threshold differs (hba1c<=11, hba1c>=6.5 versus bmi>=18, hba1c<=10.5, hba1c>=7); comorbidity_cardiovascular_disease differs (none recorded versus required).
- mPopulation comparability has not been reviewed for 65 of these studies.
- nPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Canagliflozin
show 1 more result
show 2 more results
show 2 more results
show 2 more results
+ 26 further endpoints in the CSV export.
Ertugliflozin
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 23 more results
show 13 more results
show 11 more results
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 3 more results
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · Ertugliflozin's landscape